Genta preclinical data

GNTA presented results using xenografts of human breast cancers in immunocompromised mice. G3139 gave dose-dependent inhibition of tumor growth, with 90 percent inhibition at the highest dose level. The agent was given as a subcutaneous infusion for 14 days

In other xenograft studies, there were significant reductions in the weight of human melanoma tumors. The agent, combined with the chemotherapeutic dacarbazine, virtually eliminated tumors in treated mice, while mice given only the chemotherapy continued to have melanoma tumors. Results were presented at the International Congress on Oligonucleotide Therapeutics in Rome. ...